Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Novartis sells Austrian injectable drug site

by Rick Mullin
October 31, 2020 | A version of this story appeared in Volume 98, Issue 42

 

A photo of a manufacturing plant in an idyllic setting.
Credit: Novartis
Fareva will get this facility in Austria.

Novartis has agreed to sell its injectable drug manufacturing facility in Unterach, Austria, to Fareva Group, a Luxembourg-based pharmaceutical services firm. Fareva will continue to supply Novartis. In September, Novartis agreed to sell two drug manufacturing sites in Spain—a plant making ophthalmic drugs in El Masnou and a solid-dose-form site in Barberà del Vallès—to Siegfried, a Swiss pharmaceutical services contractor.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.